Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Megan M. Herr, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Maureen Ross, Christine Ho, Jens Hillengass, Eunice S. Wang, Amanda Przespolewski, Elizabeth A. Griffiths, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Paola Ghione, Philip L. McCarthy, Theresa E. Hahn

Blood (2021) 138 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2021-150954

Published: 2021

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect

Hemn Mohammadpour, PhD DVM, Joseph L. Sarow, BS, George L. Chen, MD, Cameron R. MacDonald, BS, Umesh Sharma, MD, Megan M. Herr, PhD, Theresa E. Hahn, PhD, Elizabeth A. Repasky, PhD, Philip L. McCarthy, MD

Blood (2019) 134 (Supplement_1): 1915.

https://doi.org/10.1182/blood-2019-123139

Published: 2019

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation

Christine M. Ho, MD, Theresa Hahn, PhD, Paul K. Wallace, MS, PhD, Yali Zhang, Ahmad Fora, MD, George L. Chen, MD, Sarah A. Holstein, MD PhD, Patrick Mellors, Benjamin McCarthy, Sophia R. Balderman, MD, Philip L. McCarthy, MD

Blood (2016) 128 (22): 3454.

https://doi.org/10.1182/blood.V128.22.3454.3454

Published: 2016

Journal Articles

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors

Blood (2016) 128 (19): 2350–2358.

https://doi.org/10.1182/blood-2015-09-669846

Published: 2016

Includes: Supplemental data

Journal Articles

Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma

Pallawi Torka, MD, Paul K. Wallace, MS, PhD, Yali Zhang, George L. Chen, MD, Sophia R. Balderman, MD, Bruno Paiva, PhD, Christine M. Ho, MD, Maureen Ross, MD, Francisco J. Hernandez-Ilizaliturri, MD, Philip L. McCarthy, MD, Theresa Hahn, PhD

Blood (2015) 126 (23): 3173.

https://doi.org/10.1182/blood.V126.23.3173.3173

Published: 2015

Journal Articles

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Nicholas Leigh, Guanglin Bian, PhD, Wei Du, George L. Chen, MD, Hong Liu, MD, PhD, Philip L. McCarthy, Jr., MD, Xuefang Cao, PhD

Blood (2013) 122 (21): 3255.

https://doi.org/10.1182/blood.V122.21.3255.3255

Published: 2013

Journal Articles

Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival

Theresa Hahn, PhD, Yali Zhang, MPH, Bruno Paiva, George L. Chen, MD, Paul K. Wallace, MS, PhD, Philip L. McCarthy, Jr., MD

Blood (2013) 122 (21): 3348.

https://doi.org/10.1182/blood.V122.21.3348.3348

Published: 2013

Journal Articles

Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT)

Sophia Francis, Theresa Hahn, PhD, Yali Zhang, MPH, Nikolaos Almyroudis, MD, George L. Chen, MD, Hong Liu, MD, PhD, Maureen Ross, MD, PhD, Brahm H Segal, MD, Philip L. McCarthy, Jr., MD

Blood (2012) 120 (21): 4141.

https://doi.org/10.1182/blood.V120.21.4141.4141

Published: 2012

Journal Articles

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Sally Arai, Bita Sahaf, Balasubramanian Narasimhan, George L. Chen, Carol D. Jones, Robert Lowsky, Judith A. Shizuru, Laura J. Johnston, Ginna G. Laport, Wen-Kai Weng, Jonathan E. Benjamin, Joanna Schaenman, Janice Brown, Jessica Ramirez, James L. Zehnder, Robert S. Negrin, David B. Miklos

Blood (2012) 119 (25): 6145–6154.

https://doi.org/10.1182/blood-2011-12-395970

Published: 2012

Includes: Supplemental data

Journal Articles

Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis

George L. Chen, MD, Yali Zhang, MPH, Hong Liu, MD, PhD, Maureen Ross, MD, PhD, Theresa Hahn, PhD, Philip L. McCarthy, Jr., MD

Blood (2011) 118 (21): 3038.

https://doi.org/10.1182/blood.V118.21.3038.3038

Published: 2011

Journal Articles

Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Hong Liu, MD, PhD, Yali Zhang, MPH, Theresa Hahn, PhD, Julie Thomas, DO, Meir Wetzler, MD, Eunice S. Wang, MD, Lise Hernandez, MPH, Maureen Ross, MD, PhD, George L. Chen, MD, Philip L. McCarthy, Jr., MD

Blood (2011) 118 (21): 3096.

https://doi.org/10.1182/blood.V118.21.3096.3096

Published: 2011

Journal Articles

A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease

George L. Chen, MD, Paul A. Carpenter, MD, Raewyn Broady, MBChB, FRACP, Tara B. Gregory, MD, Sally Arai, MD, Laura Johnston, MD, Mary E.D. Flowers, MD, Jan H. Beumer, PharmD, PhD, Jodie Mendolsohn, Xin Zhou, Spenser H. Perloff, Joanne M Otani, RN, MSN, David B Miklos, MD, PhD

Blood (2011) 118 (21): 1986.

https://doi.org/10.1182/blood.V118.21.1986.1986

Published: 2011

Journal Articles

Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Hong Liu, MD, PhD, Theresa Hahn, PhD, Gregory Wilding, PhD, Adrienne Groman, Barbara Bambach, MD, Meghan Higman, MD, Maureen Ross, MD, PhD, George L. Chen, MD, Philip L. McCarthy, Jr., MD

Blood (2011) 118 (21): 4570.

https://doi.org/10.1182/blood.V118.21.4570.4570

Published: 2011

Journal Articles

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

George L. Chen, Sally Arai, Mary E. D. Flowers, Joanne M. Otani, Jingxin Qiu, Ethan C. Cheng, Alex McMillan, Laura J. Johnston, Judith A. Shizuru, David B. Miklos

Blood (2011) 118 (15): 4070–4078.

https://doi.org/10.1182/blood-2011-03-341693

Published: 2011

Includes: Supplemental data

NARROW

Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

β2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogenic Transplantation While Preserving Graft Versus Leukemia Effect

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors

Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival

Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT)

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis

Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease

Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only